Literature DB >> 22543116

High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature.

Paul L Nguyen1, Phillip M Devlin, Clair J Beard, Peter F Orio, Michael P O'Leary, Luciant D Wolfsberger, Desmond A O'Farrell, Christopher M Sweeney, Boris A Hadaschik, Markus Hohenfellner, Gencay Hatiboglu.   

Abstract

PURPOSE: To describe the use of a temporary spacer to reduce rectal dose prior to prostate radiation in a man with prior pelvic radiotherapy and review the relevant literature. METHODS AND MATERIALS: A healthy 57-year-old man presented with high-risk prostate cancer (Gleason score of 8, prostate-specific antigen level [PSA] 12.6 ng/mL, T3a by magnetic resonance imaging [MRI]), only 2.5 years after a low anterior resection followed by pelvic chemo-radiotherapy to 50.4 Gy for a locally advanced rectal cancer. Due to the prior radiation, he was not felt to be a candidate for surgery or external beam radiation, so he chose long-term androgen deprivation therapy (ADT) plus high-dose-rate brachytherapy to 36 Gy in 6 fractions. To reduce the radiation dose to the anterior rectal wall, 10 mL of a polyethylene glycol hydrogel spacer was injected between the prostate and rectum and created between 1.4 and 1.5 cm of separation along the length of the prostate.
RESULTS: Two randomized trials demonstrating that local therapy plus ADT improves overall survival compared to ADT alone provided the rationale for additional prostate radiotherapy in this otherwise healthy patient. Salvage brachytherapy is associated with a 3.4% rate of rectal fistula among the 251 cases reported in the literature from 2000-2007, with rates as high as 12% in one series. The spacer allowed the rectal dose constraint goals to be easily met.
CONCLUSIONS: Injecting an absorbable polyethylene glycol hydrogel to separate the prostate and rectum appears to be associated with decreased maximum and mean rectal doses, and may have particular utility in previously irradiated patients.
Copyright © 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543116     DOI: 10.1016/j.brachy.2012.03.005

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  5 in total

1.  Novel use of a hydrogel spacer permits reirradiation in otherwise incurable recurrent gynecologic cancers.

Authors:  Akila N Viswanathan; Antonio L Damato; Paul L Nguyen
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

Review 2.  The evolution of brachytherapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz
Journal:  Nat Rev Urol       Date:  2017-06-30       Impact factor: 14.432

3.  Application of a hydrogel spacer for postoperative salvage radiotherapy of prostate cancer.

Authors:  Michael Pinkawa; Carolin Schubert; Nuria Escobar-Corral; Richard Holy; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2014-10-23       Impact factor: 3.621

4.  Rectal separation using hydroxypropyl methylcellulose in intracavitary brachytherapy of cervical cancer: an innovative approach.

Authors:  Swapnendu Basu; Kazi Sazzad Manir; Abhishek Basu; Koushik Ghosh
Journal:  J Contemp Brachytherapy       Date:  2016-10-11

5.  Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients.

Authors:  Arndt-Christian Müller; Johannes Mischinger; Theodor Klotz; Bernd Gagel; Gregor Habl; Gencay Hatiboglu; Michael Pinkawa
Journal:  Radiol Oncol       Date:  2016-07-19       Impact factor: 2.991

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.